Albert C. Font - Publications

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.

Journal: The New England journal of medicine

Published: July 22, 2026

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.

Journal: Cancers

Published: May 29, 2026

Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 14, 2026

Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 27, 2026

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis.

Journal: The Prostate

Published: January 12, 2026

YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 03, 2025

A 5000 Fps, 4 Megapixel, Radiation-Tolerant, Wafer-Scale CMOS Image Sensor for the Direct Detection of Electrons and Photons.

Journal: Sensors (Basel, Switzerland)

Published: October 06, 2025

Corrigendum to "Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors" [Eur. Urol. Open Sci. 70 (2024) 86-90].

Journal: European urology open science

Published: June 18, 2025

Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression.

Journal: International journal of molecular sciences

Published: May 30, 2025

Corrigendum to "Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients" [Eur. Urol. Oncol. 7 (2024) 954-964].

Journal: European urology oncology

Published: May 27, 2025

Tumor-Educated Platelets in Urological Tumors: A Novel Biosource in Liquid Biopsy.

Journal: International journal of molecular sciences

Published: March 07, 2025

Spatial architecture contributes to failure of bulk biomarker-guided neoadjuvant immunotherapy selection in bladder cancer: The DUTRENEO study.

Journal: Cell reports. Medicine

Published: February 22, 2025